MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.43
-0.31
-4.60%
Closed 17:47 07/06 EDT
OPEN
6.81
PREV CLOSE
6.74
HIGH
6.85
LOW
6.30
VOLUME
424.23K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
2.210
MARKET CAP
12.49M
P/E (TTM)
-1.8414
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.

EPS

ABIO News

More
ARCA biopharma Shares Resume Trade, Continue Higher, Now Up 22.5%
Benzinga · 06/10 19:17
ARCA biopharma Shares Spike Sharply Higher, Up 14%, Halted On Circuit Breaker
Benzinga · 06/10 19:13
ARCA biopharma 13G Filing From Altium Capital Shows 9.99% Stake
Benzinga · 06/10 19:09
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
GlobeNewswire · 06/03 14:56
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
Zacks · 06/03 14:56
71 Biggest Movers From Yesterday
Gainers Cemtrex, Inc. (NASDAQ: CETX) shares climbed 172.4% to close at $2.58 on Monday following earlier press release highlighting release of new thermal body temperature measurement camera, the V1100B-THM-TEMP.
Benzinga · 06/02 08:39
MYOV, NBRV, RWLK and WWR among midday movers
Seeking Alpha - Article · 06/01 16:43
48 Stocks Moving In Monday's Mid-Day Session
Gainers Cemtrex, Inc. (NASDAQ: CETX) shares jumped 198% to $2.8199.
Benzinga · 06/01 16:34

Industry

Pharmaceuticals
+0.74%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About ABIO

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
More

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.